+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Screening for LRRK2 R1441 mutations in a cohort of PSP patients from Germany



Screening for LRRK2 R1441 mutations in a cohort of PSP patients from Germany



European Journal of Neurology 16(11): 1230-1232



Mutations in the leucine-rich repeat kinase gene (LRRK2) have been shown to be the most common genetic cause of both familial and sporadic Parkinson's disease. Patients harboring LRRK2 mutations develop late onset PD that in most cases cannot be clinically distinguished from idiopathic PD. Furthermore, LRRK2 mutations have been reported to result in a broad spectrum of neuropathological alterations including progressive supranuclear palsy (PSP)-like Tau pathology. We screened a cohort of 88 clinically confirmed PSP patients for mutations in exon 31. We did not find any of the known mutations or any new variants. Thus, there is no evidence that mutations in exon 31 of LRRK2 are a major risk factor for PSP. Our study, however, cannot rule out that other genetic variations in LRRK2 may be associated with PSP.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055670799

Download citation: RISBibTeXText

PMID: 19538213

DOI: 10.1111/j.1468-1331.2009.02702.x


Related references

Genetic screening for the LRRK2, G2019S and R1441 codon mutations in Parkinson's disease patients from Extremadura, Spain. Revista de Neurologia 50(10): 591-594, 2010

Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi. Plos One 6(6): E21352-E21352, 2011

Screening for LRRK2 mutations in patients with Parkinson's disease in Russia: identification of a novel LRRK2 variant. European Journal of Neurology 15(7): 692-696, 2008

Lrrk2 R1441 substitution and progressive supranuclear palsy. Neuropathology and Applied Neurobiology 32(1): 23-25, 2006

Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants. European Journal of Neurology 14(1): 7-11, 2007

Absence of LRRK2 mutations in a cohort of patients with idiopathic REM sleep behavior disorder. Neurology 86(11): 1072-1073, 2016

The LRRK2 gene in Parkinson's disease: mutation screening in patients from Germany. Journal of Neurology, Neurosurgery, and Psychiatry 77(7): 891-892, 2006

Screening LRRK2 gene mutations in patients with Parkinson's disease in Ghana. Journal of Neurology 259(3): 569-570, 2012

Genetic screening for the LRRK2 R1441C and G2019S mutations in Parkinsonian patients from Campania. Journal of Parkinson's Disease 4(1): 123-128, 2014

Genetic screening for two LRRK2 mutations in French patients with idiopathic Parkinson's disease. Genetic Testing 10(4): 290-293, 2007

A clinic-based screening of mutations in exons 31, 34, 35, 41, and 48 of LRRK2 in Iranian Parkinson's disease patients. Movement Disorders 24(7): 1023-1027, 2009

Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants. Parkinsonism & Related Disorders 19(10): 897-900, 2014

LRRK2 mutations in a clinic-based cohort of Parkinson's disease. European Journal of Neurology 13(12): 1298-1301, 2006

LRRK2 screening in a Canadian Parkinson's disease cohort. Canadian Journal of Neurological Sciences. le Journal Canadien des Sciences Neurologiques 34(3): 336-338, 2007

Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian. Movement Disorders 21(10): 1731-1734, 2006